Market Cap: $46.74M
OI
Oncolytics Biotech Inc.
ONCY
NASDAQUSD
Market Cap: $46.74M
Oncolytics Biotech (Ticker: ONCY) accelerates its position in the cancer therapy landscape with promising data on pelareorep, an investigational oncolytic virus. As the company reveals recent findings…
### Oncolytics Biotech Positions Itself in the Growing Immuno-Oncology Sector Oncolytics Biotech Inc. is making significant strides in the rapidly evolving oncology market, which is projected to exper…
Oncolytics Biotech Advances Treatment Options for Metastatic Colorectal Cancer Oncolytics Biotech Inc. is making strides in the battle against metastatic colorectal cancer, particularly among patients…
Oncolytics Biotech's Innovative Approach to Colorectal Cancer Treatment Oncolytics Biotech Inc. leads the charge in redefining treatment protocols in the oncology sector, particularly with its randomi…
Oncolytics Biotech Targets Critical Growth Areas in Immuno-Oncology Oncolytics Biotech Inc. is strategically aligning itself within the burgeoning immuno-oncology sector, which is poised for significa…
Oncolytics Biotech Gains Traction in Oncology Market with Promising Study Results Oncolytics Biotech Inc. is on a path to capitalize on the substantial growth opportunities within the global oncology…
Oncolytics targets an unmet need in KRAS‑mutant colorectal cancer Pelareorep’s Fast Track paves way for controlled registration study Oncolytics Biotech is advancing pelareorep toward late‑stage devel…
Regulatory Momentum Hits Targeted Oncology Oncolytics Biotech Inc. is winning accelerated regulatory attention as the U.S. Food and Drug Administration increasingly clears expedited pathways for targe…
FDA Momentum Reshapes Oncology Approval Pathway U.S. regulators are increasing the pace of expedited approvals for targeted cancer therapies, creating a faster path for drugs addressing genetically de…
Oncolytics Biotech: Strategic Positioning in Precision Oncology Oncolytics Biotech Inc. is strategically positioning itself to harness the growth potential within the precision oncology market, which…
Oncolytics Biotech Strengthens Leadership to Drive Precision Oncology Initiatives Oncolytics Biotech Inc. is making strategic advancements in the rapidly evolving precision oncology market, which is e…
Oncolytics Biotech's Pelareorep Shows Promise in Treating Anal Cancer Oncolytics Biotech Inc. is at the forefront of advancing immunotherapy with its investigational drug, pelareorep, which is making…
Oncolytics Biotech Advances Immunotherapy for Anal Cancer Oncolytics Biotech Inc. is at the forefront of oncology innovation with its investigational immunotherapy, pelareorep. Recent findings from th…
Oncolytics Biotech Advances Pelareorep for Anal Cancer Treatment Oncolytics Biotech Inc. is making notable progress in the field of oncology with its investigational immunotherapy, pelareorep. This tr…
Oncolytics Biotech Positions Pelareorep as a Leading Immunotherapy in Cancer Treatment Oncolytics Biotech Inc. is making notable advancements in the cancer drugs market, which is projected to reach $5…
Oncolytics Biotech: Pioneering Immunotherapy in Cancer Treatment Oncolytics Biotech Inc. is carving a niche for itself in the rapidly evolving cancer drugs market, which is expected to soar to $594.3…
Oncolytics Biotech's Pelareorep: A Game Changer in Immunotherapy for Colorectal and Anal Cancers Oncolytics Biotech Inc. is making notable advancements in the competitive field of cancer therapeutics,…
Oncolytics Biotech Targets Gastrointestinal Cancers with Innovative Treatments Oncolytics Biotech Inc. is at the forefront of pioneering treatments for gastrointestinal cancers, which have traditional…
Oncolytics Biotech Advances in Immuno-Oncology with Promising Study Results Oncolytics Biotech is making significant strides in the field of immuno-oncology, particularly through its lead product, pel…
Oncolytics Biotech Advances Cancer Treatment with Promising Clinical Developments Oncolytics Biotech Inc. makes significant strides in the oncology sector as it announces promising developments in cli…
Oncolytics Biotech's Promising GOBLET Study Results for SCAC Treatment Oncolytics Biotech Inc. has recently announced significant findings from its GOBLET study, which investigates the efficacy of pel…
Oncolytics Biotech Pioneers New Immunotherapy Trial for Pancreatic Cancer Oncolytics Biotech Inc. is making significant strides in the development of pelareorep, an innovative immunotherapy agent aime…
Oncolytics Biotech Pushes Forward with Promising Pancreatic Cancer Trial Oncolytics Biotech Inc., a clinical-stage immunotherapy company, announces a significant update regarding its registration-dire…
Oncolytics Biotech Expands GOBLET Trial to Enhance Treatment for Gastrointestinal Cancers Oncolytics Biotech Inc. is making significant strides in the oncology sector with its clinical-stage immunothe…
Oncolytics Biotech's Pelareorep Shows Promising Results in Colorectal Cancer Treatment Oncolytics Biotech Inc. has made significant strides in cancer treatment with its drug pelareorep, especially for…